Skip to content
Screener

Incyte INCY Total costs & expenses

Total costs & expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.89B-15.3%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$80.65M+24.9%
Gilead Sciences logo
Gilead SciencesGILD
$18.2B+295%
Geron logo
GeronGERN
$9.24M+676%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$155.3M+11.3%
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.28B+60.1%
Enterprise value$20.34B+53.5%
P/E15.1×-2.4×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative351,735331,022679,822656,713
Asset impairment and related disposal costs23,214
Loss on change in fair value of acquisition-related contingent consideration2,49922,7612,33134,333
Total costs, expenses and other976,141685,2151,947,7001,532,945
Income from operations697,898530,314999,015735,482
Interest income38,11825,13671,80548,065
Interest expense(582)(594)(1,151)(1,254)
Gain (loss) on equity investments9,805(4,151)16,396(5,494)

Item 1. Financial Statements

FAQ

What is Incyte's total costs & expenses?
Incyte (INCY) reported total costs & expenses of $976.14M in Q2 2026.
How has Incyte's total costs & expenses changed year-over-year?
Incyte's total costs & expenses increased by 42.5% year-over-year, from $685.22M to $976.14M.
What is the long-term trend for Incyte's total costs & expenses?
Over 4 years (2021 to 2025), Incyte's total costs & expenses has grown at a 10.9% compound annual growth rate (CAGR), from $2.4B to $3.63B.
What does total costs & expenses mean?
This metric represents the aggregate of all operating costs, including cost of goods sold, research and development, selling, general, and administrative expenses, and other operational charges incurred during the period. It provides a comprehensive view of the company's total operational burn rate and cost structure. Analyzing this figure relative to revenue is essential for evaluating the company's overall operational efficiency and scalability.

Ask your AI about Incyte's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude